Peer Reviewed: Numerical Simulation of Tablet Coating - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peer Reviewed: Numerical Simulation of Tablet Coating
The authors investigate the tablet-coating process using a combination of different simulation techniques.


Pharmaceutical Technology
Volume 36, Issue 9, pp. 52-55

Conclusion

Advanced numerical-simulation techniques can aid in the development and optimization of pharmaceutical tablet-coating processes. Investigating mixing performance and the resulting residence time distribution of different coating apparatus can be used to increase intra-tablet coating homogeneity. Numerical simulations of the interplay of drying air, spray, and tablet bed were used to examine both local and global coating performance. Computational results showed how the process parameters influence the film quality and coating uniformity. A usual rule-of-thumb is to place the nozzle at about one-third of the tablet bed, measured along the bed surface starting from the top. The study of different spray-nozzle setups showed that in terms of spray loss, following this rule indeed gave the best results. However, aiming the nozzle slightly away from the air inlet could reduce the amount of spray loss. Finally, inter-tablet coating variability was quantified by using the DEM method to determine the effects of tablet flow inside the coater in terms of residence time under the spray.

In addition to helping achieve a mechanistic understanding of the coating process, the computational data can be collected into in-silico design spaces, in which the correlation between critical process parameters and critical quality attributes provide an improved understanding of the design, optimization, and operation of industrial coating devices.

Gregor Toschkoff, Daniele Suzzi, PhD, and Siegfried Adam, PhD, are researchers at the Research Center for Pharmaceutical Engineering (RCPE) in Graz, Austria. Johannes Khinast*, PhD, is director of RCPE and head of the Institute for Process and Particle Engineering, Graz University of Technology, Inffeldgasse 21/a/II 8010 Graz, Austria, tel. +43 316 873 7978,
.

*To whom all correspondence should be addressed.

Submitted: Apr. 15, 2011; Accepted: Jan. 16, 2012.

References

1. A. Kalbag and C. Wassgren, Chem. Eng. Sci. 64 (11), 2705–2717 (2009).

2. D. Suzzi, S. Radl, and J.G. Khinast, Chem. Eng. Sci. 65 (21), 5699–5715 (2010).

3. B. Freireich and C. Wassgren, Chem. Eng. Sci. 65 (3), 1117–1124 (2010).

4. S. Tobiska and P. Kleinebudde, Intl. J. Pharmaceutics 224 (1–2), 141–149 (2001).

5. L. Ho et al., J. Control. Rel., 119 (3), 253–261 (2007).

6. W.R. Ketterhagen, M.T. am Ende, and B.C. Hancock, J. Pharm. Sci. 98 (2), 442–470 (2009).

7. A. Alexander, T. Shinbrot, and F.J. Muzzio, Powd. Tech. 126 (2), 174–190 (2002).

8. G. Toschkoff et al., AIChE J. 58 (2), 399–411 (2012).

9. D. Suzzi et al., Chem. Eng. Sci. 69 (1), 107–121 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here